nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Addressing unanswered questions in ovarian cancer trial methodology: follow-up of the 2004 Baden–Baden Gynecologic Cancer Intergroup meeting
|
Eisenhauer, E.A. |
|
|
18 |
S1 |
p. 74-75 |
artikel |
2 |
Can carboplatin replace cisplatin for intraperitoneal use?
|
Fujiwara, K. |
|
|
18 |
S1 |
p. 29-32 |
artikel |
3 |
First-line randomized trials: revisiting the Ptolemaic universe
|
Bookman, M.A. |
|
|
18 |
S1 |
p. 47-52 |
artikel |
4 |
Future opportunities of the Gynecological Cancer Intergroup
|
Stuart, G.C.E. |
|
|
18 |
S1 |
p. 71-73 |
artikel |
5 |
Lessons learned from a decade of clinical trials of high-dose chemotherapy in ovarian cancer
|
Ledermann, J.A. |
|
|
18 |
S1 |
p. 53-58 |
artikel |
6 |
Maintenance chemotherapy in advanced ovarian cancer: the US experience
|
Markman, M. |
|
|
18 |
S1 |
p. 40-43 |
artikel |
7 |
Management of retroperitoneal lymph nodes in advanced ovarian cancer
|
Hacker, N.F. |
|
|
18 |
S1 |
p. 7-10 |
artikel |
8 |
National Cancer Institute–United States strategy regarding intraperitoneal chemotherapy for ovarian cancer
|
Trimble, E.L. |
|
|
18 |
S1 |
p. 26-28 |
artikel |
9 |
Ovarian cancer in the proteomics era
|
Annunziata, C.M. |
|
|
18 |
S1 |
p. 1-6 |
artikel |
10 |
Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer
|
Howell, S.B. |
|
|
18 |
S1 |
p. 20-25 |
artikel |
11 |
Radiation therapy and biological compounds for consolidation therapy in advanced ovarian cancer
|
Auranen, A. |
|
|
18 |
S1 |
p. 44-46 |
artikel |
12 |
Second-line randomized trials in epithelial ovarian cancer
|
Vermorken, J.B. |
|
|
18 |
S1 |
p. 59-66 |
artikel |
13 |
Strategies to examine new compounds for intraperitoneal use in ovarian cancer
|
Markman, M. |
|
|
18 |
S1 |
p. 33-35 |
artikel |
14 |
Ten years of “Optimal Therapy in Advanced Ovarian Cancer. Update” Meeting
|
Poveda, A. |
|
|
18 |
S1 |
p. 67-70 |
artikel |
15 |
Timing of debulking surgery in advanced ovarian cancer
|
Vergote, I. |
|
|
18 |
S1 |
p. 11-19 |
artikel |
16 |
What is the optimal approach to the administration of intraperitoneal chemotherapy in ovarian cancer?
|
Markman, M. |
|
|
18 |
S1 |
p. 36-39 |
artikel |